Literature DB >> 8261423

Expression of calcyclin in human melanocytic lesions.

M A Weterman1, G N van Muijen, H P Bloemers, D J Ruiter.   

Abstract

When comparing two subsequent stages of melanocytic tumor progression we identified calcyclin as a new potential progression marker, the expression of which was correlated with metastatic behavior of various human melanoma cell lines in nude mice. In this study, we describe a good correlation between RNA and protein levels in the xenografts of these cell lines and extended these experiments to a panel of 120 routinely processed human melanocytic cutaneous lesions. Northern blot analysis demonstrated that calcyclin RNA expression was elevated in melanoma metastases as compared to several types of nevocellular nevi. Calcyclin staining using a specific polyclonal antiserum showed a more complex pattern. A stronger staining in a higher percentage of positive cells was observed in thick primary melanoma (> or = 1.5 mm) as compared to thin primary melanoma (< 1.5 mm). Calcyclin expression was also present in a higher percentage of cells showing a stronger staining in melanomas with higher Clark levels (> II) corresponding to the vertical growth phase of primary melanomas. Protein expression in nevocellular nevi was confined to the dermal part and was highest in the lower parts of the dermis. Remarkably, dysplastic nevi (atypical moles), potential precursors of melanoma, did not show any expression at all, either in junctional or dermal parts. Confinement of the expression to the dermal part of nondysplastic nevi and primary melanomas may reflect interactions with the microenvironment of the reticular dermis that occurs with vertical growth.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8261423

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Protein S100A4: too long overlooked by pathologists?

Authors:  Luca Mazzucchelli
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

2.  S100A13 is a new angiogenic marker in human melanoma.

Authors:  Daniela Massi; Matteo Landriscina; Annamaria Piscazzi; Elena Cosci; Alek Kirov; Milena Paglierani; Claudia Di Serio; Vasileios Mourmouras; Stefano Fumagalli; Maurizio Biagioli; Igor Prudovsky; Clelia Miracco; Marco Santucci; Niccolò Marchionni; Francesca Tarantini
Journal:  Mod Pathol       Date:  2010-03-05       Impact factor: 7.842

3.  Cloning, overexpression, purification, and spectroscopic characterization of human S100P.

Authors:  A Gribenko; M M Lopez; J M Richardson; G I Makhatadze
Journal:  Protein Sci       Date:  1998-01       Impact factor: 6.725

4.  Protein signatures for survival and recurrence in metastatic melanoma.

Authors:  William M Hardesty; Mark C Kelley; Deming Mi; Robert L Low; Richard M Caprioli
Journal:  J Proteomics       Date:  2011-04-23       Impact factor: 4.044

5.  Increased expression of S100A6 at the invading fronts of the primary lesion and liver metastasis in patients with colorectal adenocarcinoma.

Authors:  K Komatsu; Y Kobune-Fujiwara; A Andoh; S Ishiguro; H Hunai; N Suzuki; M Kameyama; K Murata; J Miyoshi; H Akedo; M Tatsuta; H Nakamura
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

6.  Upregulated expression of calcyclin-binding protein/siah-1 interacting protein in malignant melanoma.

Authors:  Li Zhu; Shou Miake; Ayako Ijichi; Saho Kawahara; Miki Kohno; Hiroko Sonoyama; Yasutaka Mitamura; Yumiko Kaku; Hiroko Tsuru; Yating Tu; Masutaka Furue
Journal:  Ann Dermatol       Date:  2014-09-26       Impact factor: 1.444

7.  Calcium-binding S100 protein expression in pterygium.

Authors:  Andri K Riau; Tina T Wong; Roger W Beuerman; Louis Tong
Journal:  Mol Vis       Date:  2009-02-16       Impact factor: 2.367

8.  S100A4 mediates endometrial cancer invasion and is a target of TGF-beta1 signaling.

Authors:  Ran Xie; Matthew P Schlumbrecht; Gregory L Shipley; Susu Xie; Roland L Bassett; Russell R Broaddus
Journal:  Lab Invest       Date:  2009-06-08       Impact factor: 5.662

9.  S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors.

Authors:  I Rehman; S S Cross; A-R Azzouzi; J W F Catto; J C Deloulme; S Larre; J Champigneuille; G Fromont; O Cussenot; F C Hamdy
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.